Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: major trends and deals from the recent J.P. Morgan meeting, the impact of the US Inflation Reduction Act, the pricing of Alzheimer’s drug Leqembi and five blockbusters set to lose exclusivity this year.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 13 January 2023, including: key themes and insights from the J.P. Morgan meeting; the pharma impact of the US Inflation Reduction Act; the pricing of Eisai Co., Ltd./Biogen, Inc.'s Alzheimer’s drug Leqembi; and five blockbusters set to lose exclusivity this year.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "J.P. Morgan Was Back, But Not With A Roar" - Scrip, 11 Jan, 2023.)
(Also see "J.P. Morgan Day One: Biopharma Braces For Headwinds Ahead" - Scrip, 10 Jan, 2023.)
(Also see "IRA Already Impacting Merck & Co. BD Decisions, CEO Davis Says" - Scrip, 5 Jan, 2023.)
(Also see "Eisai/Biogen’s Leqembi Will Launch Below Aduhelm At $26,500 Per Year" - Scrip, 6 Jan, 2023.)
(Also see "At The Edge Of The Cliff: Five Blockbuster Drugs Set To Lose US Patent Exclusivity In 2023" - Scrip, 5 Jan, 2023.)